RSD 944

Drug Profile

RSD 944

Alternative Names: RSD944

Latest Information Update: 27 Mar 2003

Price : $50

At a glance

  • Originator Cardiome Pharma; Rhythm Search Developments
  • Developer Cardiome Pharma; Rhythm Search Developments; University of British Columbia
  • Class Class I antiarrhythmics
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 27 Mar 2003 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)
  • 27 Jun 2001 Nortran Pharmaceuticals is now called Cardiome Pharma
  • 24 Sep 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top